Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134138) titled 'Construction and Validation of a Machine Learning-Based Predictive Model for the Efficacy and Toxicity of Teprotumumab N01 in the Treatment of Thyroid Eye Disease' on Oct. 11.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Eye & ENT hospital of Fudan University

Condition: Thyroid Eye Disease

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2026-08-06

Target Sample Size: The observation group of thyroid-related ophthalmopathy:300;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=344193

Published by HT Digi...